Gareth
Gwyn
Senior Vice President, Medical Affairs
Gareth Gwyn joined Liquidia in 2023 where he serves as Senior Vice President of Medical Affairs. In this role, Gareth leads the company’s medical strategy across pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and works closely with cross-functional partners to ensure that high-quality scientific evidence is translated into meaningful clinical understanding, enabling healthcare providers to deliver the best possible care to patients living with PAH and PH-ILD. He is also responsible for advancing Medical Affairs activities supporting YUTREPIA® and Liquidia’s proprietary PRINT® technology, with a focus on improving patient care and clinical outcomes. With more than two decades of experience in pulmonary vascular disease and Medical Affairs leadership, Gareth has dedicated his career to addressing unmet patient needs and advancing therapies that meaningfully improve quality of life. He has held senior roles across multiple biopharmaceutical companies, partnering with clinicians, investigators and patient advocacy organizations to support evidence generation, disease awareness and access to innovative treatments. Gareth holds a Bachelor of Science in Microbiology from Dalhousie University.
Gareth Gwyn joined Liquidia in 2023 where he serves as Senior Vice President of Medical Affairs. In this role, Gareth leads the company’s medical strategy across pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and works closely with cross-functional partners to ensure that high-quality scientific evidence is translated into meaningful clinical understanding, enabling healthcare providers to deliver the best possible care to patients living with PAH and PH-ILD. He is also responsible for advancing Medical Affairs activities supporting YUTREPIA® and Liquidia’s proprietary PRINT® technology, with a focus on improving patient care and clinical outcomes. With more than two decades of experience in pulmonary vascular disease and Medical Affairs leadership, Gareth has dedicated his career to addressing unmet patient needs and advancing therapies that meaningfully improve quality of life. He has held senior roles across multiple biopharmaceutical companies, partnering with clinicians, investigators and patient advocacy organizations to support evidence generation, disease awareness and access to innovative treatments. Gareth holds a Bachelor of Science in Microbiology from Dalhousie University.